Program
Carbidopa
Also written as “Carbidopa and Levodopa Controlled-Release Tablets (25 mg/150 mg)”, “Levodopa-carbidopa intestinal gel” and “Carbidopa/levodopa/entacapone”.
Its studies are mostly in Parkinson Disease · Dyskinesias · Attention Deficit Disorder with Hyperactivity · Fibromyalgia · Disruptive, Impulse Control, and Conduct Disorders, led by 7 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novartis | 80 open or running | phase 4since Jun 30, 2005 | Dec 10, 2004 | none ahead |
| AbbVie | 60 open or running | phase 3since Jun 8, 2006 | Jun 8, 2006 | none ahead |
| Orion Corporation, Orion Pharma | 30 open or running | phase 2since Feb 14, 2011 | Jun 5, 2008 | none ahead |
| Amneal Pharmaceuticals | 10 open or running | phase 1since Nov 30, 2023 | Nov 30, 2023 | none ahead |
| Osmotica Pharmaceutical US | 10 open or running | phase 2since Nov 12, 2007 | Nov 12, 2007 | none ahead |
| Shanghai WD Pharmaceutical | 10 open or running | phase 1since Feb 12, 2026 | Feb 12, 2026 | none ahead |
| SynAgile | 10 open or running | phase 2since Feb 22, 2021 | Feb 22, 2021 | none ahead |
Also a collaborator on its studies: tfs-trial-form-support and quintiles-inc.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 7 studies since Dec 10, 2004.
- Nov 12, 2007Osmotica Pharmaceutical US's first study: phase 2 study in Parkinson DiseaseNew to Osmotica Pharmaceutical USOsmotica Pharmaceutical US · NCT00558337 · 78 enrolled · Argentina
- Jan 11, 2008Phase 4 study in Parkinson DiseaseNovartis · NCT00601978
- Mar 19, 2008Phase 4 study in Parkinson DiseaseNovartis · NCT00642356 · 14 enrolled · United States
- Jun 5, 2008Orion Corporation, Orion Pharma's first study: phase 1 study in PharmacokineticsNew to Orion Corporation, Orion PharmaOrion Corporation, Orion Pharma · NCT00693862 · 19 enrolled · Finland
- Feb 14, 2011Phase 2 study in Parkinson DiseaseOrion Corporation, Orion Pharma · NCT01296464 · 27 enrolled · Finland, Sweden
- Jul 28, 2011Phase 1 study in Parkinson DiseaseAbbVie · NCT01484990 · 19 enrolled
- Sep 7, 2012Phase 4 study in Disruptive, Impulse Control, and Conduct DisordersNovartis · NCT01683253 · 150 enrolled · Korea, Republic of
- Nov 27, 2012Phase 3 study in Advanced Parkinson's DiseaseAbbVie · NCT01736176 · 39 enrolled
- Oct 9, 2013Phase 3 study in Advanced Parkinson's DiseaseAbbVie · NCT01960842 · 31 enrolled
- Sep 11, 2015Phase 3 study in Advanced Parkinson's DiseaseAbbVie · NCT02549092 · 89 enrolled · United States, Australia, Canada and more
- Jan 20, 2017Phase 1 study in Healthy VolunteersOrion Corporation, Orion Pharma · NCT03055936 · 56 enrolled · Germany
- Feb 22, 2021SynAgile's first study: phase 2 study in Parkinson DiseaseNew to SynAgileSynAgile · NCT04778176 · 17 enrolled · Italy, Luxembourg, Spain
- Nov 30, 2023Amneal Pharmaceuticals's first study: phase 1 study in Cardiac Repolarization in Healthy SubjectsNew to Amneal PharmaceuticalsAmneal Pharmaceuticals · NCT06161220 · 35 enrolled · United States
- Feb 12, 2026Shanghai WD Pharmaceutical's first study: phase 1 study in HealhtyNew to Shanghai WD PharmaceuticalShanghai WD Pharmaceutical · NCT07442591 · 12 enrolled · China
TargetBeta
“DOPA decarboxylase inhibitor”ChEMBL 37, by rule
Other programs on DDC
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| benserazide, levodopa drug combinationrule | Bial - Portela C | phase 1 | 3 |
Studies
All 21 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07442591Healhty · China | 1 | Completed | Shanghai WD Pharmaceutical | Apr 23, 2026 | 12 |
| NCT06161220Cardiac Repolarization in Healthy Subjects · United States | 1 | Completed | Amneal Pharmaceuticals | Dec 3, 2023 | 35 |
| NCT04778176Parkinson Disease · Italy, Luxembourg, Spain | 2 | Completed | SynAgile | Jul 21, 2022 | 17 |
| NCT03055936Healthy Volunteers · Germany | 1 | Completed | Orion Corporation, Orion Pharma | Jun 9, 2017 | 56 |
| NCT02549092Advanced Parkinson's Disease · United States, Australia, Canada and more | 3 | Completed | AbbVie | May 14, 2020 | 89 |
| NCT01960842Advanced Parkinson's Disease | 3 | Completed | AbbVie | Mar 2015 | 31 |
| NCT01736176Advanced Parkinson's Disease | 3 | Completed | AbbVie | Mar 2015 | 39 |
| NCT01683253Disruptive, Impulse Control, and Conduct Disorders · Korea, Republic of | 4 | Completed | Novartis | Dec 2014 | 150 |
| NCT01484990Parkinson Disease | 1 | Completed | AbbVie | Sep 2010 | 19 |
| NCT01296464Parkinson Disease · Finland, Sweden | 2 | Completed | Orion Corporation, Orion Pharma | Jul 2011 | 27 |
| NCT00693862Pharmacokinetics · Finland | 1 | Completed | Orion Corporation, Orion Pharma | Apr 2008 | 19 |
| NCT00642356Parkinson Disease · United States | 4 | Terminated | Novartis | May 2009 | 14 |
| NCT00601978Parkinson Disease | 4 | Withdrawn | Novartis | Nov 2009 | 0 |
| NCT00558337Parkinson Disease · Argentina | 2 | Completed | Osmotica Pharmaceutical US | Dec 2008 | 78 |
| NCT00391898Parkinson Disease · Spain | 4 | Completed | Novartis | Jun 2008 | 95 |
| NCT00360568Dyskinesias · United States, Germany, New Zealand | 3 | Completed | AbbVie | Oct 2012 | 62 |
| NCT00335153Dyskinesias · United States, Australia, Canada and more | 3 | Completed | AbbVie | Jun 2012 | 354 |
| NCT00143026Parkinson Disease · Australia, Philippines, Taiwan and more | 4 | Completed | Novartis | Jun 2006 | 184 |
| NCT00134966Parkinson Disease · United States, Canada, Czechia and more | 3 | Completed | Novartis | Sep 2007 | 493 |
| NCT00219284Parkinson Disease · United States, Puerto Rico | 4 | Completed | Novartis | Jul 2008 | 359 |
| NCT00099268Parkinson Disease · United States, Austria, Belgium and more | 3 | Completed | Novartis | Nov 2008 | 747 |
How it is read
Names in the registry
- “Carbidopa and Levodopa Controlled-Release Tablets (25 mg/150 mg)”, 3 entries
- “Levodopa-carbidopa intestinal gel”, 3 entries
- “Carbidopa/levodopa/entacapone”, 3 entries
- “Levodopa-Carbidopa Intestinal Gel”, 2 entries
- “Carbidopa”, 2 entries
Conditions, from the studies’ own filings
- Parkinson Disease, 16 studies
- Dyskinesias, 2 studies
- Attention Deficit Disorder with Hyperactivity, 1 study
- Fibromyalgia, 1 study
- Disruptive, Impulse Control, and Conduct Disorders, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.